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of large post tricuspid shunts in pediatric patients with severe
PAH was safe, feasible and efﬁcacious alternative to conventional
surgery.
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BACKGROUND Population studies have identiﬁed a correlation be-
tween migraine and patent foramen ovale (PFO), and observational
studies have reported that PFO closure results in improvement in
migraine in some patients. The PREMIUM Trial was a randomized,
sham-controlled, double blind study of percutaneous closure of PFO
with the AMPLATZER PFO Occluder (St. Jude Medical, Inc.) as a
treatment for migraine with or without aura.
METHODS 230 subjects with medically intractable migraine with or
without aura, who also had a patent foramen ovale (PFO), were ran-
domized to either a sham procedure plus medical therapy (107) or
percutaneous closure of the PFO plus medical therapy (123). Inclusion
criteria for randomization included 6 - 14 days of migraine per month
as assessed by a headache specialist, and failure (either lack of efﬁcacy
or intolerance) of 3 preventive medications and a signiﬁcant right to
left cardiac shunt (Spencer grade 4-5) determined by a screening
TransCranial Doppler (TCD) intravenous agitated saline study. Sub-
jects were randomized on the catheterization table after proof of a
PFO was established, to device closure versus a sham control. Subjects
and headache specialists were blinded to the randomization alloca-
tion. The primary efﬁcacy endpoint was the responder rate percent
deﬁned as a 50% reduction in migraine attacks per month based on
the diary during months 10-12 post randomization. Subjects in the
control arm could receive the device after the 1-year blind was over.
The primary safety endpoint was the proportion of subjects who
experienced a device related serious adverse event through 1 year of
follow-up.
RESULTS There was no difference in the responder rate between the
device (38%) and the control groups (32%, p¼0.3). The device was
safe: there was 1/202 (0.5%) device related serious adverse event,
which was a transient episode of atrial ﬁbrillation. Secondary
endpoint analysis showed a signiﬁcant reduction in the total number
of headache days (3.4 vs 2.0 days, p¼0.03) in the device group. A
subset analysis revealed that subjects for whom the majority of
migraine attacks included aura had a particularly signiﬁcant reduction
in headache days (19/39, 49% responder rate vs 9/40, 23% responder
rate, p¼0.015). Complete remission of migraine occurred in 10.8% (8/
74) of the device group and 1.5% (1/68) of controls who had a diagnosis
of migraine with aura (p¼0.02).
CONCLUSIONS Device closure of PFO can be performed safely, but
did not result in a 50% or greater decrease in migraine attack fre-
quency compared with a sham procedure, but there was a signiﬁcant
decrease in the mean number of headache days. Subgroup analysis
suggests that individuals with aura occurring during the majority of
their attacks may respond more favorably to PFO closure, and that a
small but signiﬁcant percentage of migraine with aura patients may
experience complete remission of migraine.
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BACKGROUND The GORE CARDIOFORM Septal Occluder (studied as
GORE Septal Occluder) was recently FDA approved for the trans-
catheter treatment of ostium secundum atrial septal defects. It is a
low proﬁle double disc device composed of a nitinol 5-wire frame, and
covered with expanded polytetraﬂuoroethylene. We present the ﬁrst
data including both Pivotal and early Continued Access trial subjects
with one year follow-up.
METHODS Patients were enrolled from 17 Pivotal and Continued Ac-
cess U.S. sites in a prospective single arm trial. Follow-up was
immediately post-procedure, and at scheduled intervals through one
year. Endpoints included successful device placement, immediate
and late closure success, and serious adverse events, including
serious device-related events requiring reintervention.
RESULTS Between October, 2012 and January, 2014, 125 patients were
enrolled with a median age of 7.4 years (range 2.4-78.6). Defects
treated had a static diameter of 10.03.2mm (maximum 17mm), and
stop ﬂow stretched diameter of 12.23.2mm (range 5.7-17.5). Deﬁcient
retroaortic rim (< 5.0 mm) was present in 36.3%, multiple fenestra-
tions in 18.4%, and atrial septal aneurysm in 10.4%. A CARDIOFORM
Septal Occluder was successfully implanted in 92% of patients (115/
125), with a serious adverse event rate of 0.8% at one year. Immediate
closure success (0-2 mm residual shunt) was 98.3% and a 2.1-4 mm
residual defect was present in 1.7%. Clinical closure success, deﬁned
as normalization of right heart size, was 100%. There were no cases of
post-procedural embolization or reintervention.
CONCLUSIONS The GORE CARDIOFORM Septal Occluder provides a
new option for percutaneous closure of small and medium-sized
secundum atrial septal defects, with high technical implant success,
occlusion rate, and safety proﬁle.
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BACKGROUND Left ventricle (LV) remodeling after anterior wall
myocardial infarction (AWMI) leads to increased LV volumes,
myocardial stress, and ultimately heart failure (HF). Treatment op-
tions are limited for these high-risk HF patients. Aims: The primary
objective is to continue to assess the long term safety of the Car-
dioKinetix Parachute Implant System in the partitioning of the
left ventricle in patients with heart failure due to ischemic heart
disease.
METHODS One hundred patients with NYHA class II-IV HF secondary
to AWMI, with akinetic or dyskinetic wall motion abnormality, and LV
ejection fraction < 40%, were enrolled in Europe. The primary
endpoint was site-reported procedural and device related MACE in
real world use of the Parachute Implant through 5 years of clinical
follow-up. In this report, two year data will be analyzed. Secondary
endpoints included changes in LVESVi and LVEDVi.
RESULTS As of the last data cut in early 2015, an analysis which
included 73 of the 100 PARACHUTE III patients, had a two year pro-
cedure / device related MACE rate of 9.2%. Two year follow-up of the
full cohort of 100 patients will be available for the TCT conference in
October 2015.
CONCLUSIONS The analysis of the post market data conﬁrms the
safety and longer term efﬁcacy of the Parachute device in treating HF.
